IVBIY.US Innovent Biologics, Inc.

Healthcare Biotechnology USA Stocks
43.00 USD
Close of Nov 14, 2026
37.54 54.29
Market cap
USD 18.7B
P/E
110.3x
P/B
6.03x
ROE
4.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is IVBIY.US undervalued?

Graham number

The Graham number of Innovent Biologics, Inc. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Innovent Biologics, Inc. fundamental analysis

No fundamental analysis for Innovent Biologics, Inc. yet.

Innovent Biologics, Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Innovent Biologics, Inc.

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases. Its commercial stage product portfolio includes TYVYT (si…

Full company profile